3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma
2
Immunoblastic Lymphadenopathy
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Prolymphocytic, T-Cell
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
tremelimumab
1
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
durvalumab
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
romidepsin
×
1 year
×
Clear all
No trials found.